睿知中国医院研究地图
候选清单

即将招募乳腺癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中山大学孙逸仙纪念医院Sun Yat-sen Memorial Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07876596,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 55 岁;性别:不限

    登记记录的入选字段

  2. Surgery within 6 months before screening, planned surgery during the study, or prior surgery affecting gastrointestinal absorption (e.g., gastrectomy, enterectomy, bariatric surgery).

    排除标准第 2 条

  3. Any positive result for HBsAg, anti-HCV, anti-TP, or anti-HIV.

    排除标准第 13 条

  4. Participants of childbearing potential (including partners) agreed to have no plans for pregnancy or sperm/egg donation from informed consent until 3 months after the last dose, and voluntarily used highly effective contraception (including partners); female participants of childbearing potential must have a negative serum HCG test within 7 days before enrollment and must be non-lactating.

    入选标准第 5 条

    Female participants who are pregnant or lactating.

    排除标准第 21 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07876596,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Signed informed consent before the trial; fully understood the trial content, procedures, and possible adverse reactions; able to complete the study per protocol.
  2. Healthy participants aged 18-55 years (inclusive) at the time of signing informed consent.
  3. At screening, male body weight ≥ 50.0 kg, female body weight ≥ 45.0 kg, and BMI 19.0-28.0 kg/m² (inclusive).
  4. Healthy participants confirmed by the investigator at screening and baseline to have no clinically significant abnormalities, including medical history, general physical examination, vital signs, laboratory tests (blood routine, urinalysis, blood biochemistry, and coagulation function), and ECG.
  5. Participants of childbearing potential (including partners) agreed to have no plans for pregnancy or sperm/egg donation from informed consent until 3 months after the last dose, and voluntarily used highly effective contraception (including partners); female participants of childbearing potential must have a negative serum HCG test within 7 days before enrollment and must be non-lactating.

排除标准:Exclusion Criteria:

  1. Any clinically significant or interfering disease involving the cardiovascular, endocrine, nervous, digestive, respiratory, urogenital, hematologic, immunologic, psychiatric, or metabolic systems.
  2. Surgery within 6 months before screening, planned surgery during the study, or prior surgery affecting gastrointestinal absorption (e.g., gastrectomy, enterectomy, bariatric surgery).
  3. Blood donation or major blood loss (≥ 400 mL), transfusion, or use of blood products within 3 months before screening.
  4. Allergic constitution, including severe drug allergy or drug hypersensitivity; history of allergy to HRS-8080, rifampicin, rifamycin, or their excipients.
  5. Frequent use of sedatives, hypnotics, or other addictive drugs; history of drug abuse within 1 year before screening; positive urine drug abuse screen.
  6. Use of hepatotoxic drugs (e.g., isoniazid, pyrazinamide, methotrexate, leflunomide, valproate, amiodarone, acetaminophen, dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for > 7 consecutive days within 2 months before screening.
  7. Participation in any clinical trial with an investigational drug within 3 months before first dosing.
  8. Use of any drug altering hepatic enzyme activity within 28 days before dosing.
  9. Use of any prescription drug or herbal medicine within 1 month, or any OTC drug or food supplement (including vitamins, calcium tablets) within 2 weeks before first dosing.
  10. Smoking > 5 cigarettes/day within 3 months before screening and unable to stop tobacco use during the study.
  11. Frequent alcohol use within 6 months before screening (> 14 units/week; 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine) and unable to stop alcohol during the study; positive alcohol breath test.
  12. Clinically significant abnormalities in vital signs, physical examination, 12-lead ECG, abdominal ultrasound, chest X-ray, blood routine, blood biochemistry, urinalysis, or coagulation at screening.
  13. Any positive result for HBsAg, anti-HCV, anti-TP, or anti-HIV.
  14. Intake of > 8 servings (1 serving = 250 mL) of caffeine-containing beverages or equivalent within 48h before first dosing and unable to abstain during the study.
  15. Intake of methylxanthine-containing beverages or foods (e.g., coffee, tea, cola, chocolate) within 48h before first dosing until study withdrawal and unwilling to stop.
  16. Intake of grapefruit-containing beverages or foods within 7 days before first dosing until study withdrawal and unwilling to stop.
  17. Special dietary requirements or inability to comply with a standardized diet.
  18. Live/attenuated vaccine within 3 months before first dosing, or planned live/attenuated/inactivated vaccine during the study (until last follow-up).
  19. Dysphagia.
  20. History of needle or blood phobia, poor venous access, difficult blood collection, or intolerance to venipuncture.
  21. Female participants who are pregnant or lactating.
  22. Any other condition deemed unsuitable for study participation by the investigator.

引自 ClinicalTrials.gov, NCT07876596, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07876596,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07876596